Skip to main
CATX
CATX logo

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc. is well-positioned for growth due to its innovative use of the alpha-emitting isotope Lead-212 (212Pb), which offers enhanced safety and efficacy in cancer treatment applications. The company's lead program, VMT-α-NET, shows promising clinical data with response rates significantly outpacing competitors like Lutathera and a strong safety profile, suggesting a strong potential market value in the neuroendocrine tumor (NET) space. Additionally, the ongoing interest and investment in radiopharmaceuticals and isotope production, as evidenced by substantial funding in the sector, indicate a healthy market environment conducive to Perspective Therapeutics's future expansion and stock appreciation.

Bears say

Perspective Therapeutics Inc faces significant challenges in the competitive landscape of radiopharmaceuticals, as demand for alpha-emitting isotopes like Actinium currently outstrips supply, creating obstacles for the company to gain market traction. The company's clinical data indicate a concerning incidence of severe treatment-emergent adverse events (TEAEs) such as anemia and decreased lymphocyte counts, which may hinder its product acceptance and future sales growth. Additionally, commercialization risks loom large due to potential difficulties in competing with established products, unfavorable pricing, and reimbursement issues, all of which could adversely impact the company’s financial stability and market position.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.